{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T20:38:19Z","timestamp":1780432699136,"version":"3.54.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273516"],"award-info":[{"award-number":["82273516"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s10067-025-07597-4","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T17:58:14Z","timestamp":1755885494000},"page":"4025-4032","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A systematic review and network meta-analysis comparing the efficacy and safety of deucravacitinib versus selected treatments for moderate to severe plaque psoriasis"],"prefix":"10.1007","volume":"44","author":[{"given":"Jiaqi","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinbo","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuewei","family":"Kan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingping","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8156-4580","authenticated-orcid":false,"given":"Jun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,22]]},"reference":[{"key":"7597_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23136955","author":"S Zhou","year":"2022","unstructured":"Zhou S, Yao Z (2022) Roles of infection in psoriasis. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23136955","journal-title":"Int J Mol Sci"},{"key":"7597_CR2","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","volume":"397","author":"CEM Griffiths","year":"2021","unstructured":"Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN (2021) Psoriasis. Lancet (London, England) 397:1301\u20131315. https:\/\/doi.org\/10.1016\/S0140-6736(20)32549-6","journal-title":"Lancet (London, England)"},{"key":"7597_CR3","doi-asserted-by":"publisher","first-page":"m1590","DOI":"10.1136\/bmj.m1590","volume":"369","author":"R Parisi","year":"2020","unstructured":"Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM (2020) National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ (Clinical Research ed) 369:m1590. https:\/\/doi.org\/10.1136\/bmj.m1590","journal-title":"BMJ (Clinical Research ed)"},{"key":"7597_CR4","doi-asserted-by":"publisher","first-page":"918224","DOI":"10.3389\/fimmu.2022.918224","volume":"13","author":"N Gao","year":"2022","unstructured":"Gao N, Kong M, Li X, Zhu X, Wei D, Ni M et al (2022) The association between psoriasis and risk of cardiovascular disease: a mendelian randomization analysis. Front Immunol 13:918224. https:\/\/doi.org\/10.3389\/fimmu.2022.918224","journal-title":"Front Immunol"},{"key":"7597_CR5","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1111\/jdv.18376","volume":"36","author":"A Pinter","year":"2022","unstructured":"Pinter A, Puig L, Sch\u00e4kel K, Reich A, Zaheri S, Costanzo A et al (2022) Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO). Journal of the European Academy of Dermatology and Venereology\u202f: JEADV 36:2087\u20132100. https:\/\/doi.org\/10.1111\/jdv.18376","journal-title":"J Eur Acad Dermatol Venereol : JEADV"},{"key":"7597_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18112297","author":"K R\u00f8nholt","year":"2017","unstructured":"R\u00f8nholt K, Iversen L (2017) Old and new biological therapies for psoriasis. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms18112297","journal-title":"Int J Mol Sci"},{"key":"7597_CR7","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1111\/jdv.14576","volume":"31","author":"WH Boehncke","year":"2017","unstructured":"Boehncke WH (2017) New biologics in psoriasis\u2014progress and problems. Journal of the European Academy of Dermatology and Venereology\u202f: JEADV 31:1577\u20131578. https:\/\/doi.org\/10.1111\/jdv.14576","journal-title":"J Eur Acad Dermatol Venereol : JEADV"},{"key":"7597_CR8","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s40265-022-01796-y","volume":"82","author":"SM Hoy","year":"2022","unstructured":"Hoy SM (2022) Deucravacitinib: first approval. Drugs 82:1671\u20131679. https:\/\/doi.org\/10.1007\/s40265-022-01796-y","journal-title":"Drugs"},{"key":"7597_CR9","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1007\/s13555-022-00760-8","volume":"12","author":"A Armstrong","year":"2022","unstructured":"Armstrong A, Fahrbach K, Leonardi C, Augustin M, Neupane B, Kazmierska P et al (2022) Efficacy of bimekizumab and other biologics in moderate to severe plaque psoriasis: a systematic literature review and a network meta-analysis. Dermatol Ther 12:1777\u20131792. https:\/\/doi.org\/10.1007\/s13555-022-00760-8","journal-title":"Dermatol Ther"},{"key":"7597_CR10","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","volume":"88","author":"B Strober","year":"2023","unstructured":"Strober B, Tha\u00e7i D, Sofen H, Kircik L, Gordon KB, Foley P et al (2023) Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 program for evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol 88:40\u201351. https:\/\/doi.org\/10.1016\/j.jaad.2022.08.061","journal-title":"J Am Acad Dermatol"},{"key":"7597_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","volume":"88","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, Gooderham M, Warren RB, Papp KA, Strober B, Thaci D et al (2023) Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol 88:29\u201339. https:\/\/doi.org\/10.1016\/j.jaad.2022.07.002","journal-title":"J Am Acad Dermatol"},{"key":"7597_CR12","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.jaad.2021.02.057","volume":"85","author":"NH Shear","year":"2021","unstructured":"Shear NH, Betts KA, Soliman AM, Joshi A, Wang Y, Zhao J et al (2021) Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: a network meta-analysis of clinical trial data. J Am Acad Dermatol 85:572\u2013581. https:\/\/doi.org\/10.1016\/j.jaad.2021.02.057","journal-title":"J Am Acad Dermatol"},{"key":"7597_CR13","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ (Clinical Research ed) 327:557\u2013560","journal-title":"BMJ (Clinical Research ed)"},{"key":"7597_CR14","doi-asserted-by":"publisher","unstructured":"Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS et al (2003) A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 139:1627\u20101632; discussion 1632. https:\/\/doi.org\/10.1001\/archderm.139.12.1627","DOI":"10.1001\/archderm.139.12.1627"},{"key":"7597_CR15","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1056\/NEJMoa030409","volume":"349","author":"CL Leonardi","year":"2003","unstructured":"Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Gottlieb AB (2003) Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349:2014\u20132022. https:\/\/doi.org\/10.1056\/NEJMoa030409","journal-title":"N Engl J Med"},{"key":"7597_CR16","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1111\/j.1365-2133.2005.06688.x","volume":"152","author":"KA Papp","year":"2005","unstructured":"Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM et al (2005) A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 152:1304\u20131312. https:\/\/doi.org\/10.1111\/j.1365-2133.2005.06688.x","journal-title":"Br J Dermatol"},{"key":"7597_CR17","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","volume":"366","author":"K Reich","year":"2005","unstructured":"Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C et al (2005) Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet (london, england) 366:1367\u20131374. https:\/\/doi.org\/10.1016\/S0140-6736(05)67566-6","journal-title":"Lancet (london, england)"},{"key":"7597_CR18","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.jaad.2006.05.027","volume":"55","author":"KB Gordon","year":"2006","unstructured":"Gordon KB, Langley RG, Leonardi C, Toth D, Menter MA, Kang S et al (2006) Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 55:598\u2013606. https:\/\/doi.org\/10.1016\/j.jaad.2006.05.027","journal-title":"J Am Acad Dermatol"},{"key":"7597_CR19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(05)67763-X","volume":"367","author":"S Tyring","year":"2006","unstructured":"Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A et al (2006) Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet (london, england) 367:29\u201335. https:\/\/doi.org\/10.1016\/S0140-6736(05)67763-X","journal-title":"Lancet (london, england)"},{"key":"7597_CR20","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","volume":"371","author":"CL Leonardi","year":"2008","unstructured":"Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y et al (2008) Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet (london, england) 371:1665\u20131674. https:\/\/doi.org\/10.1016\/S0140-6736(08)60725-4","journal-title":"Lancet (london, england)"},{"key":"7597_CR21","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","volume":"58","author":"A Menter","year":"2008","unstructured":"Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG et al (2008) Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol 58:106\u2013115. https:\/\/doi.org\/10.1016\/j.jaad.2007.09.010","journal-title":"J Am Acad Dermatol"},{"key":"7597_CR22","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","volume":"371","author":"KA Papp","year":"2008","unstructured":"Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N et al (2008) Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet (london, england) 371:1675\u20131684. https:\/\/doi.org\/10.1016\/S0140-6736(08)60726-6","journal-title":"Lancet (london, england)"},{"key":"7597_CR23","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1111\/j.1365-2133.2008.08771.x","volume":"159","author":"PC van de Kerkhof","year":"2008","unstructured":"van de Kerkhof PC, Segaert S, Lahfa M, Luger TA, Karolyi Z, Kaszuba A et al (2008) Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br J Dermatol 159:1177\u20131185. https:\/\/doi.org\/10.1111\/j.1365-2133.2008.08771.x","journal-title":"Br J Dermatol"},{"key":"7597_CR24","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1346-8138.2009.00748.x","volume":"37","author":"A Asahina","year":"2010","unstructured":"Asahina A, Nakagawa H, Etoh T, Ohtsuki M (2010) Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a phase II\/III randomized controlled study. J Dermatol 37:299\u2013310. https:\/\/doi.org\/10.1111\/j.1346-8138.2009.00748.x","journal-title":"J Dermatol"},{"key":"7597_CR25","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1056\/NEJMoa0810652","volume":"362","author":"CE Griffiths","year":"2010","unstructured":"Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N et al (2010) Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 362:118\u2013128. https:\/\/doi.org\/10.1056\/NEJMoa0810652","journal-title":"N Engl J Med"},{"key":"7597_CR26","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jdermsci.2010.04.014","volume":"59","author":"H Torii","year":"2010","unstructured":"Torii H, Nakagawa H (2010) Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. J Dermatol Sci 59:40\u201349. https:\/\/doi.org\/10.1016\/j.jdermsci.2010.04.014","journal-title":"J Dermatol Sci"},{"key":"7597_CR27","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jdermsci.2011.05.005","volume":"63","author":"TF Tsai","year":"2011","unstructured":"Tsai TF, Ho JC, Song M, Szapary P, Guzzo C, Shen YK et al (2011) Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci 63:154\u2013163. https:\/\/doi.org\/10.1016\/j.jdermsci.2011.05.005","journal-title":"J Dermatol Sci"},{"key":"7597_CR28","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/j.1346-8138.2011.01347.x","volume":"39","author":"A Igarashi","year":"2012","unstructured":"Igarashi A, Kato T, Kato M, Song M, Nakagawa H (2012) Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2\/3 clinical trial. J Dermatol 39:242\u2013252. https:\/\/doi.org\/10.1111\/j.1346-8138.2011.01347.x","journal-title":"J Dermatol"},{"key":"7597_CR29","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1056\/NEJMoa1109997","volume":"366","author":"C Leonardi","year":"2012","unstructured":"Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E et al (2012) Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 366:1190\u20131199. https:\/\/doi.org\/10.1056\/NEJMoa1109997","journal-title":"N Engl J Med"},{"key":"7597_CR30","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S0140-6736(12)60642-4","volume":"380","author":"K Papp","year":"2012","unstructured":"Papp K, Cather JC, Rosoph L, Sofen H, Langley RG, Matheson RT et al (2012) Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet (london, england) 380:738\u2013746. https:\/\/doi.org\/10.1016\/S0140-6736(12)60642-4","journal-title":"Lancet (london, england)"},{"key":"7597_CR31","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","volume":"366","author":"KA Papp","year":"2012","unstructured":"Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G et al (2012) Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 366:1181\u20131189. https:\/\/doi.org\/10.1056\/NEJMoa1109017","journal-title":"N Engl J Med"},{"key":"7597_CR32","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1365-2133.2012.10941.x","volume":"167","author":"K Reich","year":"2012","unstructured":"Reich K, Ortonne JP, Gottlieb AB, Terpstra IJ, Coteur G, Tasset C, Mease P (2012) Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab\u2019 certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. Br J Dermatol 167:180\u2013190. https:\/\/doi.org\/10.1111\/j.1365-2133.2012.10941.x","journal-title":"Br J Dermatol"},{"key":"7597_CR33","first-page":"1845","volume":"125","author":"HZ Yang","year":"2012","unstructured":"Yang HZ, Wang K, Jin HZ, Gao TW, Xiao SX, Xu JH et al (2012) Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled multicenter trial. Chin Med J 125:1845\u20131851","journal-title":"Chin Med J"},{"key":"7597_CR34","doi-asserted-by":"publisher","first-page":"e376","DOI":"10.1111\/j.1468-3083.2012.04716.x","volume":"27","author":"KA Papp","year":"2013","unstructured":"Papp KA, Kaufmann R, Tha\u00e7i D, Hu C, Sutherland D, Rohane P (2013) Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. Journal of the European Academy of Dermatology and Venereology\u202f: JEADV 27:e376-383. https:\/\/doi.org\/10.1111\/j.1468-3083.2012.04716.x","journal-title":"J Eur Acad Dermatol Venereol : JEADV"},{"key":"7597_CR35","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/bjd.12110","volume":"168","author":"KA Papp","year":"2013","unstructured":"Papp KA, Langley RG, Sigurgeirsson B, Abe M, Baker DR, Konno P et al (2013) Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol 168:412\u2013421. https:\/\/doi.org\/10.1111\/bjd.12110","journal-title":"Br J Dermatol"},{"key":"7597_CR36","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/bjd.12112","volume":"168","author":"P Rich","year":"2013","unstructured":"Rich P, Sigurgeirsson B, Thaci D, Ortonne JP, Paul C, Schopf RE et al (2013) Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol 168:402\u2013411. https:\/\/doi.org\/10.1111\/bjd.12112","journal-title":"Br J Dermatol"},{"key":"7597_CR37","first-page":"166","volume":"12","author":"X Zhu","year":"2013","unstructured":"Zhu X, Zheng M, Song M, Shen YK, Chan D, Szapary PO, Wang B (2013) Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS). J Drugs Dermatol 12:166\u2013174","journal-title":"J Drugs Dermatol"},{"key":"7597_CR38","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","volume":"386","author":"H Bachelez","year":"2015","unstructured":"Bachelez H, van de Kerkhof PC, Strohal R, Kubanov A, Valenzuela F, Lee JH et al (2015) Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet (london, england) 386:552\u2013561. https:\/\/doi.org\/10.1016\/S0140-6736(14)62113-9","journal-title":"Lancet (london, england)"},{"key":"7597_CR39","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/bjd.13348","volume":"172","author":"A Blauvelt","year":"2015","unstructured":"Blauvelt A, Prinz JC, Gottlieb AB, Kingo K, Sofen H, Ruer-Mulard M et al (2015) Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol 172:484\u2013493. https:\/\/doi.org\/10.1111\/bjd.13348","journal-title":"Br J Dermatol"},{"key":"7597_CR40","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1056\/NEJMoa1501646","volume":"373","author":"KB Gordon","year":"2015","unstructured":"Gordon KB, Duffin KC, Bissonnette R, Prinz JC, Wasfi Y, Li S et al (2015) A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis. N Engl J Med 373:136\u2013144. https:\/\/doi.org\/10.1056\/NEJMoa1501646","journal-title":"N Engl J Med"},{"key":"7597_CR41","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40259-022-00569-z","volume":"37","author":"Y Jiang","year":"2023","unstructured":"Jiang Y, Chen Y, Yu Q, Shi Y (2023) Biologic and small-molecule therapies for moderate-to-severe psoriasis: focus on psoriasis comorbidities. BioDrugs\u202f: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy 37:35\u201355. https:\/\/doi.org\/10.1007\/s40259-022-00569-z","journal-title":"BioDrugs : Clin Immunotherapeutics, Biopharmaceuticals Gene Ther"},{"key":"7597_CR42","doi-asserted-by":"publisher","unstructured":"Sbidian E, Chaimani A, Garcia-Doval I, Doney L, Dressler C, Hua C et al (2022) Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev 5:CD011535. https:\/\/doi.org\/10.1002\/14651858.CD011535.pub5","DOI":"10.1002\/14651858.CD011535.pub5"},{"key":"7597_CR43","doi-asserted-by":"publisher","unstructured":"Catlett IM, Hu Y, Gao L, Banerjee S, Gordon K, Krueger JG (2022) Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis. J Allergy Clin Immunol 149. https:\/\/doi.org\/10.1016\/j.jaci.2021.11.001","DOI":"10.1016\/j.jaci.2021.11.001"},{"key":"7597_CR44","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40265-020-01261-8","volume":"80","author":"M Nogueira","year":"2020","unstructured":"Nogueira M, Puig L, Torres T (2020) JAK inhibitors for treatment of psoriasis: focus on selective TYK2 inhibitors. Drugs 80:341\u2013352. https:\/\/doi.org\/10.1007\/s40265-020-01261-8","journal-title":"Drugs"},{"key":"7597_CR45","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/1346-8138.16593","volume":"50","author":"S Takano-Kawasaki","year":"2023","unstructured":"Takano-Kawasaki S, Sato E, Yamaguchi K, Imafuku S (2023) Trends in prescriptions of oral medications for psoriasis: a single-center retrospective study. J Dermatol 50:82\u201388. https:\/\/doi.org\/10.1111\/1346-8138.16593","journal-title":"J Dermatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07597-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07597-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07597-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:27:00Z","timestamp":1760365620000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07597-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["7597"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07597-4","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,22]]},"assertion":[{"value":"2 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethics approval was needed because data were retrieved from previously published studies in which informed consent was obtained by the primary investigators.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}